Market Cap
$705.5M
PHAR
Pharming Group N.V.
$9.75 ▼ -2.01%
Prev close $9.95Market cap$705.5M
ConsensusStrong Buy
12-mo target$34.35 (+252.3%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)3 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PHAR right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (93%)
Inst. Holders
8 funds
Inst. Value
$339.0K
Inst. Activity
0 buys / 3 sells
SEC Reports
7
Price chart 30d -14.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 29, 2026 announcement
Sep 11, 2026 SEC Pharming announces CEO transition
Pharming announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. C
Pharming announced FDA approval of its sNDA for Joenja (leniolisib) to treat children aged 4-11 years with APDS, expandi
6-K — Impact 7/10
Pharming announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4+, following NHI drug p
6-K — Impact 6/10
Jun 30, 2026 Inst.
BNP PARIBAS FINANCIAL MARKETS — TRIM
300 shares ($4.2K)
Jun 30, 2026 Inst.
Jun 4, 2026 SEC NewEdge Advisors, LLC — NEAR_EXIT
187 shares ($2.6K)
Pharming announced FDA acceptance of its resubmitted sNDA for Joenja (leniolisib) to treat children aged 4-11 with APDS,
6-K — Impact 7/10
May 28, 2025 Event
JOENJA
Supplemental Approval — Labeling — LENIOLISIB — TABLET — ORAL
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
93% rate it Buy or better · 14 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Sep 14, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Aug 3, 2026 | Canaccord Genuity | MAINTAIN | Buy | 47% |
| Apr 10, 2026 | Canaccord Genuity | INITIATE | Buy | 47% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Aug 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Jul 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Jun 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 7 | 6 | 1 | 0 | 0 | 93% |
Price targets
Where 4 covering analysts think PHAR trades over the next 12 months.
$34.35 +252.3% upside Strong Buy
Current$9.75 Low$23.40 Median$37.50 High$39.00 4 analysts
$23.40$39.00
Analyst rating Strong Buy· 1.0/5 as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
7 SEC filing reports analyzed · 5 bullish, 0 bearish, 0 mixed, 2 neutral · avg impact 5.9/10.
BULLISH6-K7/10
Pharming announced FDA approval of its sNDA for Joenja (leniolisib) to treat children aged 4-11 year
Sep 11, 2026
BULLISH6-K6/10
Pharming announced the commercial launch of Joenja (leniolisib) in Japan for APDS patients aged 4+,
Aug 13, 2026
BULLISH6-K7/10
Pharming announced FDA acceptance of its resubmitted sNDA for Joenja (leniolisib) to treat children
Jun 4, 2026
NEUTRAL6-K3/10
Pharming Group N.V. filed a 6-K reporting the results of its 2026 Annual General Meeting of Sharehol
May 28, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 29, 2026
announcement
Pharming announces CEO transition
Pharming announced that the Board of Directors and Fabrice Chouraqui have mutually agreed that Mr. Chouraqui will step down as CEO and Executive.
Sep 25, 2026
regulatory
Pharming announces U.S. FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children with APDS
Pharming announces US FDA acceptance and Priority Review of sNDA for lower doses of Joenja® to treat children aged 4 years older
Sep 18, 2026
Clinical Trial
Leniolisib for Immune Dysregulation in CVID
Phase Phase 2 — COMPLETED
Sep 18, 2026
clinical_trial_readout
Results Pending: Leniolisib (Phase 2) — Completed 37d ago
Trial: Leniolisib for Immune Dysregulation in CVID Sponsor: Pharming Technologies B.V. Phase: Phase 2 | Completed: 2026-08-12 Conditions: Common Varia
Aug 7, 2026
other
Pharming Group (PHAR) Securities Investigation Notice - Levi & Korsinsky
Pharming Group told investors to expect up to $425 million in 2026 revenue. The Company now expects as little as $375 million -- and the stock lost 22
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.20 | $0.20–$0.20 | 1900.0% | +143.9% | — | $0.1B | 1 |
| Next Q | $0.27 | $0.27–$0.27 | 285.7% | +151.6% | — | $0.1B | 1 |
| Current FY | $0.46 | $0.46–$0.46 | 1050.0% | +99.7% | — | $0.4B | 1 |
| Next FY | $0.31 | $0.05–$0.79 | -33.3% | +368.7% | — | $0.4B | 3 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.200 | — |
| 7d ago | $0.082 | +0.118 |
| 30d ago | $0.082 | +0.118 |
| 60d ago | $0.072 | +0.128 |
| 90d ago | $0.050 | +0.150 |
Institutional ownership
Which big funds own PHAR (from quarterly 13F filings) and who is adding or trimming.
8 institutional holders with $339.0K total value (24,699 shares) as of 2026-Q2. Top holders: CITADEL, MORGAN, Integrated. Net selling activity: 3 institutions trimmed/exited vs 0 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | 11,972 | $162.3K | 47.9% | — |
| MORGAN STANLEY | 11,500 | $159.7K | 47.1% | ADD +49.2% |
| Integrated Wealth Concepts LLC | 380 | $5.3K | 1.6% | — |
| BNP PARIBAS FINANCIAL MARKETS | 300 | $4.2K | 1.2% | TRIM -25.0% |
| Optiver Holding B.V. | 305 | $4.1K | 1.2% | — |
| NewEdge Advisors, LLC | 187 | $2.6K | 0.8% | NEAR_EXIT -91.3% |
| UBS Group AG | 39 | $542.00 | 0.2% | — |
| OSAIC HOLDINGS, INC. | 16 | $222.00 | 0.1% | NEAR_EXIT -87.5% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 400 | 300 | -25.0% | $4.2K |
| NewEdge Advisors, LLC | NEAR_EXIT | 2,150 | 187 | -91.3% | $2.6K |
| OSAIC HOLDINGS, INC. | NEAR_EXIT | 128 | 16 | -87.5% | $222.00 |
| MORGAN STANLEY | ADD | 7,700 | 11,489 | +49.2% | $191.2K |
| NewEdge Advisors, LLC | NEAR_EXIT | 28,868 | 2,150 | -92.6% | $35.8K |
| BNP PARIBAS FINANCIAL MARKETS | TRIM | 800 | 400 | -50.0% | $6.7K |
| NewEdge Advisors, LLC | DOUBLED | 253 | 28,868 | +11310.3% | $510.1K |
| MORGAN STANLEY | ADD | 4,355 | 7,700 | +76.8% | $136.1K |
| BNP PARIBAS FINANCIAL MARKETS | DOUBLED | 100 | 800 | +700.0% | $14.1K |
| MORGAN STANLEY | ADD | 2,900 | 4,355 | +50.2% | $63.1K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PHAR.
Shares short
20,882
Settlement Sep 15, 2026
Change vs prior
-16.6%
Semi-monthly cycle
Days to cover
1.2
At avg daily volume
Of shares outstanding
≈0.0%
Estimate — not % of float
All PHAR filing & press-release reports (7)
- 6-K reportSep 11, 2026
- 6-K reportAug 13, 2026
- 6-K reportJun 4, 2026
- 6-K reportMay 28, 2026
- 6-K reportMay 22, 2026
- 6-K reportApr 16, 2026
- 6-K reportMar 27, 2026